The anti-inflammatory agent infliximab, a tumor necrosis factor inhibitor, has become a cornerstone of IBD immunotherapy, underscoring the potential of targeting oxidative stress as a therapeutic strategy [21]. Here, TNF is linked to irritable bowel syndrome.